-
2023-504870-39-00
drug-drug interactions (DDI) 3
-
2025-521830-27-00
Post-bariatric hypoglycaemia 3
-
2025-522244-40-00
It is used to treat symptomatic anaemia in chronic rena 3
-
2025-522246-43-00
Treatment of symptomatic anemia associated with chronic 3
-
2025-523677-41-00
Prevention of thromboembolic events 3 2026-05-06
-
2024-513069-37-00
Healthy 1 2026-01-30
-
2025-523301-15-00
Vasodilatory shock 1 2025-12-17
-
2023-504215-32-00
Overweight and obesity 9 2023-09-28
-
2025-525076-29-00
Phase I study in healthy male volunteers. Intended indi 3 2026-03-23
-
2024-519165-22-00
Post-bariatric hypoglycaemia 3 2025-11-04
-
2024-519316-13-00
Phase I study in healthy male and female volunteers. In 1 2025-08-01
-
2024-517512-30-00
Cardiac arrhythmia 1 2025-04-28
-
2024-515757-24-00
Soil-transmitted helminth infection 3 2025-02-04
-
2024-515954-26-00
Phase I Study in healthy male and female volunteers.
In 3 2024-11-19
-
2024-512841-17-00
Healthy 3 2024-09-04
-
2024-513845-36-00
Phase I study in healthy male volunteers.
Intended indi 3 2024-08-13
-
2023-509488-26-00
Prevention of ischemic stroke in patients after an acut 3 2024-07-18
-
2024-512101-60-00
Phase I study in healthy male volunteers.
Intended indi 3 2024-06-05
-
2023-508905-26-00
Onchocerciasis (river blindness): is an infectious dise 3 2024-05-06
-
2023-503864-17-00
Vasomotor Symptoms as a sex hormone-dependent disorder 3 2023-09-20
-
2023-503368-18-00
Pulmonary hypertension due to left heart disease 1 2023-09-14
-
2022-502866-25-00
Sepsis associated disseminated intravascular coagulatio 1 2023-08-18
-
2022-503037-63-00
Phase I, Clinical trial in healthy males and females
in 3 2023-08-17
-
2022-502319-12-00
Alport syndrome 1 2023-05-30